Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.
Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. Ylisaukko-Oja T, et al. Among authors: silvennoinen j. Biologicals. 2019 Mar;58:50-56. doi: 10.1016/j.biologicals.2019.01.007. Epub 2019 Feb 10. Biologicals. 2019. PMID: 30755369 Clinical Trial.
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. Ylisaukko-Oja T, et al. Among authors: silvennoinen j. Scand J Gastroenterol. 2018 Feb;53(2):158-167. doi: 10.1080/00365521.2017.1416160. Epub 2017 Dec 19. Scand J Gastroenterol. 2018. PMID: 29258369
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H. Dignass AU, et al. Among authors: silvennoinen j. Clin Gastroenterol Hepatol. 2009 Jul;7(7):762-9. doi: 10.1016/j.cgh.2009.04.004. Epub 2009 Apr 16. Clin Gastroenterol Hepatol. 2009. PMID: 19375519 Clinical Trial.
27 results